查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614051

药物製剂市场：按剂型、技术、治疗领域和最终用户 - 2025-2030 年全球预测

Drug Formulation Market by Dosage Form, Technology, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，药物製剂市场价值为2.42兆美元，预计2024年将达到2.55兆美元，复合年增长率为5.70%，到2030年将达到3.56兆美元。

药物製剂的范围包括将化合物创造成安全有效的药物供患者使用。它涉及确定药物的成分、剂型、功效、稳定性和药物传输机制。药物製剂的需求源自于提高生物有效性度、确保安全性和延长药物保存期限的需要。应用范围涵盖製药、食品和生物技术产业，最终用途集中于患者治疗需求、动物用药品和临床试验。关键的成长要素包括慢性病的增加、人口老化、技术进步以及製药公司研发支出的增加。最新的潜在商机在于基因组和蛋白质体学研究驱动的个人化医疗和生技药品的扩展，以及奈米技术等药物传递系统，可以显着提高治疗的功效和标靶性。为了抓住这些机会，公司需要投资研发合作并采用多功能製造流程。

主要市场统计
基准年[2023] 2.42兆美元
预计年份 [2024] 2.55兆美元
预测年份 [2030] 3.56兆美元
复合年增长率（%） 5.70%

然而，市场面临着巨大的挑战，包括复杂的法律规范、高昂的开发成本以及通常与药物配方相关的冗长的核准流程。此外，来自学名药和生物製药的竞争可能会阻碍市场成长。考虑到这些因素，创新应集中于开发具有改进的递送系统的製剂，例如口服薄膜製剂和经皮贴剂製剂。探索环保製程和永续方法可以提高成本效率并应对不断提高的环境标准。药物製剂市场是一个由技术和临床进步驱动的充满活力的市场，但由于监管变化和经济状况而继续受到外部压力。为了保持成长并获得竞争优势，公司应寻求策略伙伴关係，将数位技术纳入製剂开发，并透过适应性强的药物输送解决方案来应对新兴市场。

市场动态：揭示快速发展的药物製剂市场的关键市场洞察

供需的动态交互作用正在改变药品製剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性病流行及有效治疗的必要性
    • 政府鼓励药物开发和发现的倡议
    • 个人化医疗和客製化医疗的兴起
  • 市场限制因素
    • 药品和药品召回问题
  • 市场机会
    • 药物传输和给药技术的进步
    • 学名药开发CDMO投资
  • 市场挑战
    • 复杂配方的开发与加工

波特五力：驾驭药物製剂市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解药品製剂市场的外部影响

外部宏观环境因素在塑造药物製剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解药品製剂市场的竞争状况

对药物製剂市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵药物製剂市场供应商绩效评估

FPNV定位矩阵是评估药品製剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製药物製剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，药物製剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和有效治疗的需要
      • 政府鼓励药物开发和发现的努力
      • 个人化医疗和治疗方法的兴起
    • 抑制因素
      • 因不利事件而召回
    • 机会
      • 药物传输和给药技术的进步
      • 学名药开发CDMO投资
    • 任务
      • 药物配方的复杂开发与加工
  • 市场区隔分析
    • 剂型：口服製剂在慢性治疗的便利性与有效性
    • 最终用户：药厂加大药物研发投资
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章以剂型分類的药物製剂市场

  • 吸入製剂
    • 干粉吸入器
    • 喷雾器
    • 加压定量吸入器
  • 口服製剂
    • 胶囊
    • 软糖
    • 锭剂和锭剂
    • 粉末/颗粒
    • 药片
  • 肠外製剂
    • 乳液
    • 凝胶
    • 粉末
    • 解决方案
    • 暂停
  • 局部製剂
    • 霜、乳液、泡沫
    • 凝胶剂、酊剂、粉末
    • 软膏和油
    • 贴上
    • 喷雾和补丁

第七章药物製剂市场：依技术分类

  • 速效製剂
  • 脂质体製剂
  • 微球製剂
  • 改良释放製剂
  • 奈米配方
  • 自乳化给药系统
  • 固体分散体製剂

第八章依治疗领域分類的药物製剂市场

  • 心血管
  • 中枢神经系统
  • 皮肤科
  • 内分泌学
  • 胃肠道
  • 免疫学
  • 感染疾病
  • 肿瘤学
  • 眼科
  • 疼痛管理
  • 呼吸系统

第九章药物製剂市场：依最终使用者分类

  • 学术/研究机构
  • 合约开发和製造组织
  • 医院/诊所
  • 製药公司

第十章美洲药物製剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太药物製剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲药品製剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Glenmark 在印度推出针对 2 型糖尿病患者的三重药物配方
    • Neurocline Biosciences 宣布美国FDA 已接受其 INGREZZA（Valbenazine）口服颗粒喷剂新药申请
    • 默克和 XtalPi 合作利用人工智慧技术优化药物处方
  • 战略分析和建议

公司名单

  • 3M Company
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca plc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Catalent, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gerresheimer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Marksans Pharma Ltd.
  • Medicef Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd.
  • The Bristol-Myers Squibb Company
Product Code: MRR-351BAD50373D

The Drug Formulation Market was valued at USD 2.42 trillion in 2023, expected to reach USD 2.55 trillion in 2024, and is projected to grow at a CAGR of 5.70%, to USD 3.56 trillion by 2030.

The scope of drug formulation encompasses the creation of chemical compounds into safe and effective drugs for patient use. It involves determining the drug's composition, dosage form, efficacy, stability, and delivery mechanism. The necessity for drug formulation arises from the requirement to enhance bioavailability, ensure safety, and extend the drug's shelf life. Applications are widespread across pharmaceuticals, nutritional supplements, and biotechnology industries, with end-use focused on patient therapeutic needs, veterinary medicine, and clinical trials. Key growth factors include rising chronic diseases, an aging population, technological advancements, and increased R&D expenditure by pharmaceutical companies. The latest potential opportunities lie in personalized medicine and biologics, driven by genomics and proteomics research, and the expansion of drug delivery systems such as nanotechnology, which can significantly improve the efficacy and targeting of therapeutic agents. To seize these opportunities, companies must invest in R&D collaborations and adopt versatile manufacturing processes.

KEY MARKET STATISTICS
Base Year [2023] USD 2.42 trillion
Estimated Year [2024] USD 2.55 trillion
Forecast Year [2030] USD 3.56 trillion
CAGR (%) 5.70%

However, the market faces formidable challenges, such as complex regulatory frameworks, high development costs, and the lengthy approval processes often associated with drug formulation. Furthermore, competition from generic drugs and biopharmaceuticals can hinder market growth. In light of these factors, innovation should focus on developing formulations with improved delivery systems, such as oral thin films and transdermal patches. Research in eco-friendly processes and sustainable practices could lead to cost efficiency and meet rising environmental standards. The drug formulation market is dynamic, driven by technological and clinical advancements, but remains subject to external pressures from regulatory changes and economic conditions. To maintain growth and gain competitive edge, companies should pursue strategic partnerships, embrace digital technologies for formulation development, and cater to emerging markets with adaptive drug delivery solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Formulation Market

The Drug Formulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for effective treatments
    • Government initiatives encouraging drug development and discovery
    • Rise of personalized and tailored medicine and therapies
  • Market Restraints
    • Adverse recalls of drugs and medications
  • Market Opportunities
    • Advancements in drug delivery and dosage technologies
    • Investments in CDMOs to develop generic drugs
  • Market Challenges
    • Complex development and processing of drug formulations

Porter's Five Forces: A Strategic Tool for Navigating the Drug Formulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Formulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Formulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Formulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Formulation Market

A detailed market share analysis in the Drug Formulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Formulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Formulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Formulation Market

A strategic analysis of the Drug Formulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Form, market is studied across Inhalation Formulations, Oral Formulations, Parenteral Formulations, and Topical Formulations. The Inhalation Formulations is further studied across Dry Powder Inhaler, Nebulizer, and Pressurized Metered Dose Inhaler. The Oral Formulations is further studied across Capsules, Gummies, Lozenges & Pastilles, Powders & Granules, and Tablets. The Parenteral Formulations is further studied across Emulsions, Gels, Powders, Solutions, and Suspensions. The Topical Formulations is further studied across Creams, Lotions, & Foams, Gels, Tinctures, & Powders, Ointments & Oils, Pastes, and Sprays & Patches.
  • Based on Technology, market is studied across Immediate-Release Formulations, Liposomal Formulations, Microsphere Formulations, Modified-Release Formulations, Nanoformulations, Self-Emulsifying Drug Delivery Systems, and Solid Dispersion Formulations.
  • Based on Therapeutic Area, market is studied across Cardiovascular, Central Nervous System, Dermatology, Endocrinology, Gastrointestinal, Immunology, Infectious Diseases, Oncology, Ophthalmology, Pain Management, and Respiratory.
  • Based on End User, market is studied across Academic & Research Institutions, Contract Development & Manufacturing Organizations, Hospitals & Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
      • 5.1.1.2. Government initiatives encouraging drug development and discovery
      • 5.1.1.3. Rise of personalized and tailored medicine and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of drugs and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery and dosage technologies
      • 5.1.3.2. Investments in CDMOs to develop generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex development and processing of drug formulations
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
    • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Formulation Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Inhalation Formulations
    • 6.2.1. Dry Powder Inhaler
    • 6.2.2. Nebulizer
    • 6.2.3. Pressurized Metered Dose Inhaler
  • 6.3. Oral Formulations
    • 6.3.1. Capsules
    • 6.3.2. Gummies
    • 6.3.3. Lozenges & Pastilles
    • 6.3.4. Powders & Granules
    • 6.3.5. Tablets
  • 6.4. Parenteral Formulations
    • 6.4.1. Emulsions
    • 6.4.2. Gels
    • 6.4.3. Powders
    • 6.4.4. Solutions
    • 6.4.5. Suspensions
  • 6.5. Topical Formulations
    • 6.5.1. Creams, Lotions, & Foams
    • 6.5.2. Gels, Tinctures, & Powders
    • 6.5.3. Ointments & Oils
    • 6.5.4. Pastes
    • 6.5.5. Sprays & Patches

7. Drug Formulation Market, by Technology

  • 7.1. Introduction
  • 7.2. Immediate-Release Formulations
  • 7.3. Liposomal Formulations
  • 7.4. Microsphere Formulations
  • 7.5. Modified-Release Formulations
  • 7.6. Nanoformulations
  • 7.7. Self-Emulsifying Drug Delivery Systems
  • 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrinology
  • 8.6. Gastrointestinal
  • 8.7. Immunology
  • 8.8. Infectious Diseases
  • 8.9. Oncology
  • 8.10. Ophthalmology
  • 8.11. Pain Management
  • 8.12. Respiratory

9. Drug Formulation Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Development & Manufacturing Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Formulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
    • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
    • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. AbbVie Inc.
  • 3. Amgen, Inc.
  • 4. AstraZeneca plc.
  • 5. Bayer AG
  • 6. Boehringer Ingelheim International GmbH
  • 7. Boston Scientific Corporation
  • 8. Catalent, Inc.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. Gerresheimer AG
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline plc
  • 14. Glenmark Pharmaceuticals Limited
  • 15. Halozyme Therapeutics, Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Marksans Pharma Ltd.
  • 18. Medicef Pharma
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Sanofi SA
  • 23. Teva Pharmaceuticals Industries Ltd.
  • 24. The Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG FORMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 248. FRANCE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 256. GERMANY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. GERMANY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 264. ISRAEL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. ISRAEL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. ISRAEL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 272. ITALY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. ITALY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. ITALY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. ITALY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 280. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 288. NIGERIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 289. NIGERIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. NIGERIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. NIGERIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. NIGERIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 293. NIGERIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. NIGERIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. NORWAY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 296. NORWAY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 297. NORWAY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 298. NORWAY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 299. NORWAY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. NORWAY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. NORWAY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 302. NORWAY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. POLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 304. POLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 305. POLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 306. POLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 307. POLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. POLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. POLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 310. POLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. QATAR DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 312. QATAR DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. QATAR DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 314. QATAR DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. QATAR DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. QATAR DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. QATAR DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 318. QATAR DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. RUSSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 320. RUSSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 321. RUSSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. RUSSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 323. RUSSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. RUSSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. RUSSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 326. RUSSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 328. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 332. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 333. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 334. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 336. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 338. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 342. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. SPAIN DRU